Arcline Investment Management’s Acquisition of Polypeptide Therapeutic Solutions

Cuatrecasas advised Arcline Investment Management on the deal. Arcline Investment Management (“Arcline”), a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, executed the acquisition of Polypeptide...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here